Oh was Chief Medical Officer for the
Prostate Cancer Foundation, the world’s leading philanthropy for prostate cancer. He also served as CMO for Sema4, a publicly traded genomics and health intelligence company. For 11 years, Oh was Chief of the Division of Hematology and Medical Oncology at The
Mount Sinai Medical Center in
New York City, Deputy Director at Mount Sinai's NCI-designated Tisch Cancer Institute, Professor of Medicine and Urology and the Ezra M. Greenspan, M.D., Professor in Clinical Cancer Therapeutics at The
Icahn School of Medicine at Mount Sinai.[1]
Oh is the author of more than 350 articles and 125 abstracts. He is the editor of 6 books and the author of 25 book chapters. He has been listed in Castle Connolly's "America's Top Doctors for Cancer" from 2008 to 2024, "Best Doctors in America" from 2003 to 2024, was listed among
New York Magazine's "Top Doctors" from 2010–2024.[1][2] He is on the faculty at Mount Sinai as Clinical Professor of Medicine in the Tisch Cancer Institute.
From 1997 to 2009, Oh served on the faculty of
Harvard Medical School, where he was Associate Professor of Medicine and Clinical Director of the Lank Center for Genitourinary Oncology. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine.[1]
He co-edited the book Mount Sinai Expert Guides: Oncology which was published in 2019.
Oh has been the principal investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer[3][4] and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients.
At the Dana–Farber Cancer Institute, from 2000 to 2009, Oh developed and managed a prospective clinical database linked to blood and tissue banks for more than 8,000 prostate cancer patients, with links to blood samples and tissue repositories, for exploration of research and prognostic applications, including: efficacy of various therapies in CRPC,
hormonal therapy,
testosterone as a marker for cancer outcome, relapse predictions based on nutritional factors at diagnosis and
autoantibody signatures, and assessment of
pharmacogenomic patterns predicting
Gleason score.[5] At Mount Sinai, he continued this work and developed a clinicogenomic database that resulted in multiple publications.
Oh WK, Hayes J, Evan C, et al. (June 2006). "Development of an integrated prostate cancer research information system". Clin Genitourin Cancer. 5 (1): 61–6.
doi:
10.3816/CGC.2006.n.019.
PMID16859581.
Oh WK,
Landrum MB, Lamont EB, McNeil BJ, Keating NL (March 2010). "Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?". Urology. 75 (3): 642–7.
doi:
10.1016/j.urology.2009.08.008.
PMID19962733.
Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK (November 2012). "A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study". Lancet Oncol. 13 (11): 1105–13.
doi:
10.1016/S1470-2045(12)70263-2.
PMID23059047.
Jun T, Oh WK (July 2022). ""Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?"". JAMA Oncol. 8 (7): 972–974.
doi:
10.1001/jamaoncol.2022.0511.
PMID35551363.